Fig 6.

Cumulative proportions of patients relapsing in the 12 months after various treatment steps in total therapy 2 (TT2) with thalidomide (TT2 + THAL) versus TT2 without thalidomide (TT2 − THAL) versus total therapy 1 (TT1). Additional abbreviations used: Tx1, 1st transplant, Tx2, 2nd transplant. (A) Among patients without cytogenetic abnormalities, high proportions of patients relapsed soon after Tx1 and Tx2 as part of TT1, whereas such disease escape was lower in frequency and later in timing of onset in patients treated with TT2. (B) Among patients with cytogenetic abnormalities, overall relapse rates were higher and the timing of their onset earlier when compared to patients without cytogenetic abnormalities [see (A)]. Among patients enrolled in TT1, relapse rates exceeded those after TT2 for Tx1, Tx2 and maintenance; the addition of THAL in maintenance appeared to suppress relapse in comparison with TT2 − THAL.